The best — and worst — biotech IPOs in the class of 2017

When we start­ed out this year, sev­er­al an­a­lysts re­marked that 2017 would ba­si­cal­ly be OK for biotech IPOs. Noth­ing like the go-go days of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.